Leaderboards/Diabetes Treatment and Management

Diabetes Treatment and Management

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Patricia J. Rodriguez
Bellevue College
2
Lindsey Wang
Case Western Reserve University
3
Mohit Sodhi
University of British Columbia
4
Dariush Mozaffarian
Tufts University
5
Clara Luna-Marco
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
6
Mette Kruse Klausen
Frederiksberg Hospital
7
Lasse Maretty
Novo Nordisk (Denmark)
8
Safia Chatur
Brigham and Women's Hospital
9
Simon Birk Kjær Jensen
University of Copenhagen
10
Kimberley El
Duke Medical Center

Papers

1
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
JAMA Internal Medicine|2024
268 cit.
2
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity
JAMA Network Open|2025
265 cit.
3
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes
JAMA Network Open|2024
254 cit.
4
Publication in EClinicalMedicine (2024) [174 citations, W4391943471]
EClinicalMedicine|2024
174 cit.
5
Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes
Gastroenterology|2024
117 cit.
6
Publication in JAMA Network Open (2024) [113 citations, W4400001604]
JAMA Network Open|2024
113 cit.
7
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Free Radical Biology and Medicine|2024
97 cit.
8
Publication in Obesity (2025) [82 citations, W4410893328]
Obesity|2025
82 cit.
9
Publication in Nature Medicine (2025) [66 citations, W4406051813]
Nature Medicine|2025
66 cit.
10
Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data
JNCI Journal of the National Cancer Institute|2024
42 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Anna-Maria Langkilde
AstraZeneca (Finland)
2
William Zigrang
Memphis VA Medical Center
3
Katelyn Brown
Eli Lilly (United States)
4
Trisha Mandal
All India Institute of Medical Sciences
5
Murray Gordon
University of Glasgow
6
John Lentz
Launchpad Central (United States)
7
John Cooper
University of Glasgow
8
John Marcus Fleming
University of Glasgow
9
Richard Pratley
Translational Research Institute for Metabolism and Diabetes
10
Domenica Rubino
Washington Center for Weight Management and Research

Papers

1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
New England Journal of Medicine|2024
1.5k cit.
2
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Nephrology Dialysis Transplantation|2023
237 cit.
3
Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the <scp>STEP</scp> 1–4 trials
Diabetes Obesity and Metabolism|2024
39 cit.
4
A Large-Scale, Multiplayer Virtual Reality Deployment: A Novel Approach to Distance Education in Human Anatomy
Medical Science Educator|2023
32 cit.
5
Managing Adverse Effects of Incretin-Based Medications for Obesity
JAMA|2025
26 cit.
6
Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials
Obesity|2024
20 cit.
7
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the <scp>SURMOUNT</scp> ‐1 to ‐4 trials
Diabetes Obesity and Metabolism|2025
17 cit.
8
FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease
Nephrology Dialysis Transplantation|2022
6 cit.
9
Exploring the Role of Virtual Reality in STEM Distance Education and Remote Outreach Opportunities
The Journal of STEM Outreach|2023
4 cit.
10
Treating obesity to optimize women’s health outcomes
Menopause The Journal of The North American Menopause Society|2025
3 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Jens J. Holst
University of Copenhagen
2
John B. Buse
Unknown
3
Kelly L. Close
Close Concerns (United States)
4
Daniel J. Drucker
University of Toronto
5
Bernard Zinman
Mount Sinai Hospital
6
Silvio E. Inzucchi
Yale University
7
Faı̈ez Zannad
Centre d’Investigation Clinique Innovation Technologique de Nancy
8
Michael Gnant
Austrian Breast & Colorectal Cancer Study Group
9
Marc S. Sabatine
Brigham and Women's Hospital
10
John J.V. McMurray
University of Glasgow

Papers

1
International Diabetes Federation 2017
Journal of Diabetes|2018
13.6k cit.
2
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine|2015
12k cit.
3
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
The Lancet|1994
8.5k cit.
4
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
The Lancet|1998
8.4k cit.
5
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine|2016
7.3k cit.
6
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
New England Journal of Medicine|2019
6.9k cit.
7
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
New England Journal of Medicine|2014
6.8k cit.
8
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine|2018
6.3k cit.
9
2013 ESH/ESC Guidelines for the management of arterial hypertension
Journal of Hypertension|2013
5.7k cit.
10
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
New England Journal of Medicine|2020
5k cit.

Reagents for Diabetes Treatment and Management

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Phospho-Stat3 (Tyr705) Antibody

Cited in 13 papers
#9131$362,852
View Evidence →
Cell Signaling TechnologyEvidence 65

RhoA (67B9) Rabbit Monoclonal Antibody

Cited in 12 papers
#2117$152,351
View Evidence →
Cell Signaling TechnologyEvidence 63

Apaf-1 (D7G4) Rabbit Monoclonal Antibody

Cited in 10 papers
#8723$152,351
View Evidence →

🌟 All-Time

Most validated

AbcamEvidence 60

SGLT2 antibody

Cited in 19 papers
#ab85626
View Evidence →
Cell Signaling TechnologyEvidence 66

ELMO1 (D4K2E) Rabbit Monoclonal Antibody

Cited in 19 papers
#14457$161,351
View Evidence →
Cell Signaling TechnologyEvidence 64

LIN28A (D1A1A) Rabbit Monoclonal Antibody

Cited in 13 papers
#8641$161,384
View Evidence →